Drug
Onvansertib clinical trials
Also written PCM-075, NMS-1286937 and Polo-like Kinase 1 Inhibitor NMS-1286937.
- studies test it
- 12
- open now
- 3
- in phase 3
- 0
- first study started
- 2009
Keep track of what changes. Save the onvansertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 6
Cardiff Oncology (5) · OHSU Knight Cancer Institute (2) · University of Kansas Medical Center (1) · Antonio Giordano, MD (1) · Nerviano Medical Sciences (1) · Mayo Clinic (1) · University of Maryland, Baltimore (1)
Often tested with
Tested in the same studies.
FOLFIRI-Ziv-aflibercept Regimen (2) · FOLFIRI Regimen (2) · Paclitaxel (2) · Fluorouracil/Liposomal Irinotecan/Leucovorin/Oxaliplatin Regimen (1) · Folfox protocol (1) · Irinotecan sucrosofate (1) · Leucovorin (1) · Fluorouracil (1)
Studies
Open first, then newest update. How each study uses onvansertib is read from its arms, and is right about nine times in ten.
Testing it · 12
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Onvansertib
- Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsRecruitingPhase 1Mayo ClinicNCT05549661Written as Onvansertib
- Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerRecruitingPhase 2University of Maryland, BaltimoreNCT05450965Written as Onvansertib
- Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic CancerActive, not recruitingPhase 1/2University of Kansas Medical CenterNCT06736717Written as Onvansertib
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationActive, not recruitingPhase 2Cardiff OncologyNCT06106308Written as Onvansertib
- Onvansertib + Paclitaxel In TNBCActive, not recruitingPhase 1/2Antonio Giordano, MDNCT05383196Written as Onvansertib
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaCompletedPhase 2Cardiff OncologyNCT04752696Written as Onvansertib
- Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationCompletedPhase 1/2Cardiff OncologyNCT03829410Written as Onvansertib
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationCompletedPhase 2Cardiff OncologyNCT05593328Written as Onvansertib
- Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Cardiff OncologyNCT03414034Written as Onvansertib
- Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal AdenocarcinomaWithdrawnPhase 2OHSU Knight Cancer InstituteNCT06398587Written as Onvansertib
- Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid TumorsCompletedPhase 1Nerviano Medical SciencesNCT01014429Written as NMS-1286937
Given in every arm · 1 — onvansertib is usual care beside what is tested
Codes
What other systems call onvansertib · ClinicalTrials.gg INT001307
- MeSH (NLM) C000706408onvansertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 67RM91WDHQONVANSERTIBConfirmed FDA, NLM
- NCI Thesaurus C143162OnvansertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706408 | onvansertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 67RM91WDHQ | ONVANSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C143162 | Onvansertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.